Innovations with impact Resources | Sustainable Consumer Chemicals

Algae-based, Pharma-grade Cannabinoids

Toranto | Canada

Algae-based flexible production platform to develop pharmaceutical-grade cannabinoids.

FSD Pharma and Solarvest BioEnergy have formed a collaborative research and development agreement to conduct research using algal expression technology to develop pharmaceutical-grade cannabinoids (CBD).

Manufacturing pharma-grade cannabinoids remains a challenge, especially for those that are found in only trace amounts in the cannabis plant. The more than 100 rare cannabinoids may hold very important medical benefits, but they make up less than 1% of the cannabis plant, making it economically prohibitive to extract and purify for pharmaceutical use.

The algae-based route for deriving CBD could prove to be more economical and practical.

Source : ...


Solarvest will use its algal expression system for the purpose of developing a proof of concept that algae can express pharmaceutical-grade cannabinoids.

Relevant industries

  • Pharma
  • Know more about this innovation from

    "Behind the Buzz" Show: FSD Pharma Inc. CEO & Co-Chairman Raza Bokhari

    FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for certain central nervous system disorders and autoimmune diseases of the skin, GI tract and musculoskeletal system, including chronic pain and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.

    Know more
    FSD signs non-binding LOI with Solarvest BioEnergy to develop/test pharma-grade cannabinoids

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's LOI with Solarvest BioEnergy to Develop and Test Production of Pharma-Grade Cannabinoids from Algae - Video Available on

    Know more

    Search key words

  • Biosynthesis of pharmaceutical-grade cannabinoids
  • Medical benefits of cannabinoids
  • Unique health benefits of cannabinoids
  • New sources for cannabinoids
  • Algae based CBD
  • Algae-based cannabinoids

  • Learn more around this innovation

    Biosynthesis Platform for Pharmaceutical-Grade Cannabinoids

    InMed is developing a biosynthesis platform to manufacture pharmaceutical-grade, cost-effective cannabinoids. Plant extraction is not feasible to meet long-term pharmaceutical demand of cannabinoid therapeutics, particularly rare cannabinoids.

    Learn more

    Related News for